Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06731907 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT06731907 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 90 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06731907, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This study aims to determine the effectiveness of adding other treatments, including the human epidermal growth factor receptor 3-directed antibody-drug conjugate (HER3-DXd) patritumab deruxtecan, to pembrolizumab, with or without chemotherapy. The primary goals are to assess safety and efficacy of the treatments.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Nab-paclitaxel
Study Locations (20)
Other
- European Interbalkan Medical Center-Oncology Department ( Site 0205) - Thessaloniki
- Országos Korányi Pulmonológiai Intézet ( Site 0060) - Budapest
- Rambam Health Care Campus ( Site 0076) - Haifa
- Shaare Zedek Medical Center ( Site 0075) - Jerusalem
- Meir Medical Center ( Site 0071) - Kfar Saba
- Rabin Medical Center ( Site 0074) - Petah Tikva
- Sheba Medical Center ( Site 0070) - Ramat Gan
- Sourasky Medical Center ( Site 0077) - Tel Aviv
Region M. de Santiago
- Centro de Estudios Clínicos SAGA ( Site 0162) - Santiago
- FALP ( Site 0161) - Santiago
- Bradfordhill ( Site 0160) - Santiago
Kentucky
- University of Kentucky ( Site 0019) - Lexington
Maryland
- MedStar Franklin Square Medical Center ( Site 0033) - Baltimore
North Dakota
- Sanford Fargo Medical Center ( Site 0039) - Fargo
Pennsylvania
- Abramson Cancer Center ( Site 0010) - Philadelphia
South Dakota
- Sanford Cancer Center ( Site 0038) - Sioux Falls
Attica
- THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 0204) - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-03-30 |
| Est. Completion | 2032-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06731907
The ClinicalTrials.gov registry entry for NCT06731907 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06731907 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Region M. de Santiago, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06731907 about?
NCT06731907 is a clinical study titled "A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)". Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This study...
What is the current status of trial NCT06731907?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-03-30. Estimated completion is 2032-03-12.
What conditions does trial NCT06731907 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06731907?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06731907?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06731907 being conducted?
This trial has 20 study locations across Kentucky, Maryland, North Dakota, Pennsylvania, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.